Board member Eric Schmidt resigns; cites compliance for new sell-side analyst role

RELMADA THERAPEUTICS, INC.

Eric Schmidt resigned from the Board effective September 5, 2023, with no disagreement with the company or management.
Resignation due to compliance requirements from his new role as a sell-side equity analyst at a Wall Street investment banking firm.
Schmidt served as a Class I director since 2019, chaired the Audit Committee, and was on the Governance Committee.
No replacement has been announced for the vacant board position.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Eric Schmidt

Member of the Board of Directors

RLMD · RELMADA THERAPEUTICS, INC.

Effective: 2023-09-05
Filed: September 6, 2023, 7:59 PM ET

On September 5, 2023, Eric Schmidt, a member of the Board of Directors (the “Board”) of Relmada Therapeutics, Inc. (the “Company”), notified the Company that he would resign from the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Eric Schmidt resigned as Member of the Board of Directors at RELMADA THERAPEUTICS, INC..

Action: resigned
Role: Member of the Board of Directors

Exact text from the filing

On September 5, 2023, Eric Schmidt, a member of the Board of Directors (the “Board”) of Relmada Therapeutics, Inc. (the “Company”), notified the Company that he would resign from the Board, effective immediately.

View on SEC.gov

RELMADA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-074165

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.